[Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
Gustafsson
Lars L
LL
Avdelningen för klinisk farmakologi, Karolinska Universitetssjukhuset vid Huddinge. Lars-L.Gustafsson@labmed.ki.se
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D017410:Practice Guidelines as Topic; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D017292:Doxazosin